RESEARCH PEPTIDE FUNDAMENTALS / MATRIX
Four Compounds, Four Very Different Evidence Bases
Lined up on the dimension this hub cares about most — how much human evidence actually exists — before mechanism, regulatory status, or anything else.
The short version
This page lines up ipamorelin, KPV, tesamorelin, and tirzepatide on the dimensions a skeptical reader should check before trusting any claim about a research peptide: how much of the evidence is human versus animal versus cell culture, what regulatory status (if any) the compound has achieved, how the mechanism actually works, and what the sourcing-and-purity risk looks like for material obtained outside a clinical trial or pharmacy. The headline: these four span the entire range, from a tripeptide with zero human trials (KPV) to a drug with multiple large randomized trials and an approved indication (tirzepatide). None of this is medical advice, and no human dose is recommended anywhere on this page.
The comparison matrix
| Dimension | Ipamorelin | KPV | Tesamorelin | Tirzepatide |
|---|---|---|---|---|
| Compound class | Selective ghrelin-receptor (GHS-R1a) agonist | Melanocortin-derived anti-inflammatory tripeptide | GHRH-receptor agonist (GHRH analogue) | Dual GIP/GLP-1 receptor agonist |
| Deepest evidence tier | One human RCT (missed primary endpoint) [3] | Cell culture and mouse colitis models only [6][7][8][9][10] | Multiple large human RCTs [11][13][15][16] | Multiple large human RCTs, incl. head-to-head [18][21][22] |
| Human trials published | 1 (postoperative ileus, negative) [3] | 0 | 5+ (HIV lipodystrophy) [11][13][14][15][16] | 4+ (diabetes, obesity) [18][19][21][22] |
| Regulatory status | Not approved anywhere | Not approved anywhere | FDA-approved (HIV lipodystrophy only) | FDA-approved (T2D, weight management) |
| Most-studied application | GH release / recovery physiology | Colitis / intestinal inflammation (mice) | Visceral fat reduction in HIV lipodystrophy | Type 2 diabetes and obesity |
| Key evidence-quality caution | Efficacy trial failed its primary endpoint [3] | No human data exists at all [6][7][8][9][10] | Strong data narrowly scoped to one indication [17] | Deepest evidence base here, but real GI/gallbladder signal [20] |
Compound class and mechanism
The four compounds work through genuinely different pathways, which is worth stating plainly because "research peptide" is often used as if it described one mechanism rather than four. Ipamorelin activates the ghrelin receptor to trigger a single pulse of growth hormone. KPV is not a hormone-receptor agonist in the same sense at all — it works through NF-kB and MAP-kinase suppression after being transported into inflamed tissue by a peptide transporter, a mechanism specific to inflammatory signaling rather than the endocrine axis the other three touch. Tesamorelin activates the GHRH receptor to stimulate the body's own growth-hormone rhythm. Tirzepatide activates two separate incretin receptors (GIP and GLP-1) simultaneously. Grouping all four under one "peptide" umbrella, as most retail sites do, obscures how little the pharmacology of one predicts the pharmacology of another.
Evidence maturity — the dimension this hub weighs most heavily
This is where the four genuinely separate, and it is the single most important column in the matrix above. Tirzepatide sits at one end: multiple randomized trials with thousands of combined participants, including a direct head-to-head comparison [18][21][22], plus independent clinical-reference confirmation of its mechanism and approved indication [19]. Tesamorelin sits close behind it — real randomized trials, a genuine FDA approval — but scoped to one specific population (HIV-associated lipodystrophy), with a much thinner evidence base for the off-label uses that generate most public interest [17]. Ipamorelin sits far below both: its only controlled human trial did not meet its primary endpoint [3], leaving pharmacokinetic data [4] and animal studies [1][2][5] as the remaining evidence. KPV sits at the far end: a real, replicated mechanism, but entirely within cell culture and mouse models [6][7][8][9][10], with no human trial published at any phase. A skeptical reader should weight claims about each compound accordingly — the same confident tone in marketing copy does not correspond to the same underlying evidence across these four.
Regulatory status
Only two of the four have ever been approved as drugs anywhere: tesamorelin (HIV-associated lipodystrophy, 2010) and tirzepatide (type 2 diabetes, 2022; chronic weight management, 2023). Ipamorelin and KPV have no approved indication in any jurisdiction and are sold exclusively as research chemicals. That distinction is not a minor technicality — an approval requires the sponsor to have run the trials, and for ipamorelin specifically, the one trial that was run did not succeed [3]. Absence of approval does not always mean absence of trying; sometimes it means the trial happened and the result was negative.
Sourcing and purity risk
This is the frame this entire hub is organized around, and it applies unevenly across the four. Ipamorelin and KPV are available only as unregulated research-chemical products, with no pharmaceutical quality assurance on either purity or identity — a fact this desk treats as at least as important as the compounds' mechanistic promise. Tesamorelin and tirzepatide are approved pharmaceuticals with manufacturing oversight when obtained through legitimate prescription channels — but both are also widely sold as "research-grade" material outside those channels, and that gray-market supply carries the same unverified-purity problem as the never-approved compounds. In other words: regulatory approval of the molecule does not automatically extend quality assurance to every vial sold under its name. Sourcing risk and evidence quality are related but separate questions, and this matrix tracks both.
Key caution, compound by compound
For ipamorelin, the defining caution is that its one human efficacy trial failed to meet its primary endpoint [3] — a fact regularly omitted from promotional material. For KPV, it is the complete absence of human trials behind a confidently marketed mechanism [6][7][8][9][10]. For tesamorelin, it is the gap between a genuinely strong trial record for one narrow indication and the much weaker evidence for the broader uses it is actually discussed for [17]. For tirzepatide, the caution is not an evidence gap at all — it is a real, well-quantified safety signal (elevated gallbladder/biliary disease risk) that a strong trial record was able to detect and confirm with statistical precision [20]. Read together, the pattern is not "more evidence means safer" — it is that more evidence means clearer answers, whatever those answers turn out to be.